ACER
Income statement / Annual
Last year (2022), Acer Therapeutics Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2022, Acer Therapeutics Inc.'s net income was -$27.86 M.
See Acer Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
Operating Revenue |
$0.00 |
$1.26 M |
$0.00 |
$0.00 |
$432,116.00 |
-$246,304.00 |
$2.91 M |
$2.56 M |
$1.27 M |
$1.27 M |
Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$0.00
|
$1.26 M
|
$0.00
|
$0.00
|
$432,116.00
|
-$246,304.00
|
$2.91 M
|
$2.56 M
|
$1.27 M
|
$1.27 M
|
Gross Profit Ratio |
0
|
1
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
Research and Development Expenses |
$11.92 M
|
$6.51 M
|
$11.85 M
|
$13.85 M
|
$12.45 M
|
$8.73 M
|
$6.50 M
|
$10.04 M
|
$12.12 M
|
$9.18 M
|
General & Administrative Expenses |
$12.69 M
|
$10.70 M
|
$10.95 M
|
$16.05 M
|
$9.26 M
|
$5.22 M
|
$3.12 M
|
$4.26 M
|
$3.83 M
|
$3.67 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$12.69 M
|
$10.70 M
|
$10.95 M
|
$16.05 M
|
$9.26 M
|
$5.22 M
|
$3.12 M
|
$4.26 M
|
$3.83 M
|
$3.67 M
|
Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$10,629.00
|
$68,695.00
|
$2,147.00
|
$37,910.00
|
Operating Expenses |
$24.61 M
|
$17.21 M
|
$22.80 M
|
$29.90 M
|
$21.71 M
|
$13.95 M
|
$9.86 M
|
$14.65 M
|
$16.34 M
|
$13.19 M
|
Cost And Expenses |
$24.61 M
|
$17.21 M
|
$22.80 M
|
$29.90 M
|
$21.71 M
|
$13.95 M
|
$9.86 M
|
$14.65 M
|
$16.34 M
|
$13.19 M
|
Interest Income |
$1,821.53
|
$49.27
|
$13,578.00
|
$471,267.00
|
$412,553.00
|
$14,848.00
|
$0.00
|
$0.00
|
$15,456.00
|
$14,985.00
|
Interest Expense |
$101,432.00
|
$0.00
|
$0.00
|
$0.00
|
$987.00
|
$245,061.00
|
$0.00
|
$0.00
|
$1,983.00
|
$2.27 M
|
Depreciation & Amortization |
-$198,470.00
|
-$54,757.00
|
$96,202.00
|
-$8,205.00
|
$27,744.00
|
$3,997.00
|
$238,127.00
|
$351,403.00
|
$387,779.00
|
$335,597.00
|
EBITDA |
-$24.55 M |
-$15.88 M |
-$22.73 M |
-$28.34 M |
-$21.25 M |
-$13.95 M |
-$6.70 M |
-$2.57 M |
-$14.66 M |
-$11.53 M |
EBITDA Ratio |
0
|
-12.7
|
0
|
0
|
-49.29
|
56.57
|
-1.95
|
-4.59
|
-11.53
|
-9.1
|
Operating Income Ratio |
0
|
-12.66
|
0
|
0
|
-50.25
|
56.63
|
-2.75
|
-4.73
|
-11.85
|
-9.41
|
Total Other Income/Expenses Net |
-$1.62 M
|
$574,396.00
|
-$82,624.00
|
-$1.02 M
|
$433,103.00
|
-$246,304.00
|
-$1.28 M
|
$74,606.00
|
$15,620.00
|
-$4.73 M
|
Income Before Tax |
-$26.24 M
|
-$15.37 M
|
-$22.89 M
|
-$29.42 M
|
-$21.28 M
|
-$14.19 M
|
-$7.98 M
|
-$12.02 M
|
-$15.05 M
|
-$16.66 M
|
Income Before Tax Ratio |
0
|
-12.2
|
0
|
0
|
-49.25
|
57.63
|
-2.75
|
-4.7
|
-11.83
|
-13.15
|
Income Tax Expense |
$1.62 M
|
-$645,309.00
|
$11,810.00
|
-$537,754.00
|
-$432,116.00
|
$246,304.00
|
$1.04 M
|
-$4,744.00
|
$4,130.00
|
$2.31 M
|
Net Income |
-$27.86 M
|
-$14.73 M
|
-$22.90 M
|
-$28.88 M
|
-$21.28 M
|
-$14.19 M
|
-$7.98 M
|
-$12.02 M
|
-$15.05 M
|
-$16.66 M
|
Net Income Ratio |
0
|
-11.69
|
0
|
0
|
-49.25
|
57.63
|
-2.75
|
-4.7
|
-11.83
|
-13.15
|
EPS |
-1.77 |
-1.03 |
-2.06 |
-2.86 |
-2.49 |
-3.84 |
-11.72 |
-21.26 |
-39.65 |
-91.56 |
EPS Diluted |
-1.77 |
-1.03 |
-2.06 |
-2.86 |
-2.49 |
-3.84 |
-11.72 |
-21.26 |
-39.65 |
-91.56 |
Weighted Average Shares Out |
$15.77 M
|
$14.27 M
|
$11.12 M
|
$10.09 M
|
$8.56 M
|
$3.69 M
|
$680,668.00
|
$565,345.00
|
$379,627.00
|
$181,924.00
|
Weighted Average Shares Out Diluted |
$15.77 M
|
$14.27 M
|
$11.12 M
|
$10.09 M
|
$8.56 M
|
$3.69 M
|
$680,668.00
|
$565,345.00
|
$379,627.00
|
$181,924.00
|
Link |
|
|
|
|
|
|
|
|
|
|